Silence Therapeutics (SLN) Competitors

$7.13 +0.15 (+2.15%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$7.01 -0.12 (-1.74%)

As of 05/14/2026 07:03 PM Eastern

SLN vs. OLMA, JBIO, MLTX, CALT, and MPLT

Should you buy Silence Therapeutics stock or one of its competitors? MarketBeat compares Silence Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Silence Therapeutics include Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO), MoonLake Immunotherapeutics (MLTX), Calliditas Therapeutics AB (publ) (CALT), and Maplight Therapeutics (MPLT). These companies are all part of the "pharmaceutical products" industry.

How does Silence Therapeutics compare to Olema Pharmaceuticals?

Silence Therapeutics (NASDAQ:SLN) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Silence Therapeutics presently has a consensus target price of $55.00, suggesting a potential upside of 671.39%. Olema Pharmaceuticals has a consensus target price of $44.10, suggesting a potential upside of 219.10%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Silence Therapeutics is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Olema Pharmaceuticals had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 13 mentions for Olema Pharmaceuticals and 10 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.75 beat Olema Pharmaceuticals' score of -0.12 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Olema Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Silence Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$839K	401.40	-$88.61M	-$1.59	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Olema Pharmaceuticals has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Olema Pharmaceuticals' return on equity of -46.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Silence Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Silence Therapeutics beats Olema Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to Jade Biosciences?

Silence Therapeutics (NASDAQ:SLN) and Jade Biosciences (NASDAQ:JBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

98.7% of Silence Therapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 23.1% of Jade Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Silence Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, Jade Biosciences had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 13 mentions for Jade Biosciences and 10 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.75 beat Jade Biosciences' score of -0.50 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Jade Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Silence Therapeutics presently has a consensus target price of $55.00, suggesting a potential upside of 671.39%. Jade Biosciences has a consensus target price of $34.33, suggesting a potential upside of 42.28%. Given Silence Therapeutics' higher probable upside, research analysts plainly believe Silence Therapeutics is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Silence Therapeutics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$839K	401.40	-$88.61M	-$1.59	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Jade Biosciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Jade Biosciences' return on equity of -51.34% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Jade Biosciences	N/A	-51.34%	-47.32%

Summary

Jade Biosciences beats Silence Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Silence Therapeutics compare to MoonLake Immunotherapeutics?

Silence Therapeutics (NASDAQ:SLN) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Silence Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

In the previous week, MoonLake Immunotherapeutics had 17 more articles in the media than Silence Therapeutics. MarketBeat recorded 27 mentions for MoonLake Immunotherapeutics and 10 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.75 beat MoonLake Immunotherapeutics' score of 0.59 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	7 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Silence Therapeutics presently has a consensus target price of $55.00, suggesting a potential upside of 671.39%. MoonLake Immunotherapeutics has a consensus target price of $23.85, suggesting a potential upside of 29.67%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Silence Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

Silence Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$839K	401.40	-$88.61M	-$1.59	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. MoonLake Immunotherapeutics' return on equity of -85.15% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Summary

Silence Therapeutics beats MoonLake Immunotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to Calliditas Therapeutics AB (publ)?

Silence Therapeutics (NASDAQ:SLN) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Silence Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$839K	401.40	-$88.61M	-$1.59	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Silence Therapeutics had 10 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 10 mentions for Silence Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Silence Therapeutics' average media sentiment score of 0.75 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silence Therapeutics	Positive
Calliditas Therapeutics AB (publ)	Neutral

Silence Therapeutics presently has a consensus target price of $55.00, suggesting a potential upside of 671.39%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Silence Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -105.34% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Silence Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

Summary

Silence Therapeutics beats Calliditas Therapeutics AB (publ) on 12 of the 17 factors compared between the two stocks.

How does Silence Therapeutics compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Silence Therapeutics (NASDAQ:SLN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Silence Therapeutics has higher revenue and earnings than Maplight Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$39.65	N/A
Silence Therapeutics	$839K	401.40	-$88.61M	-$1.59	N/A

98.7% of Silence Therapeutics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Maplight Therapeutics had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 12 mentions for Maplight Therapeutics and 10 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.75 beat Maplight Therapeutics' score of 0.13 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Maplight Therapeutics currently has a consensus target price of $34.43, indicating a potential upside of 17.54%. Silence Therapeutics has a consensus target price of $55.00, indicating a potential upside of 671.39%. Given Silence Therapeutics' higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Maplight Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Maplight Therapeutics' return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

Summary

Maplight Therapeutics beats Silence Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Silence Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLN vs. The Competition

Export

Metric	Silence Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$329.69M	$3.06B	$6.34B	$12.37B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	-4.48	18.70	20.66	25.63
Price / Sales	401.40	271.92	542.63	76.59
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	6.79	4.42	9.93	6.97
Net Income	-$88.61M	$72.19M	$3.55B	$333.62M
7 Day Performance	2.30%	-0.43%	1.70%	1.09%
1 Month Performance	-2.06%	-0.96%	0.49%	3.08%
1 Year Performance	77.81%	45.81%	39.41%	35.68%

Silence Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLN Silence Therapeutics	2.8416 of 5 stars	$7.13 +2.1%	$55.00 +671.4%	+75.6%	$329.69M	$839K	N/A	100	Earnings Report Analyst Revision
OLMA Olema Pharmaceuticals	2.2858 of 5 stars	$14.61 -0.1%	$44.40 +203.9%	+207.1%	$1.27B	N/A	N/A	70	Earnings Report Analyst Forecast Analyst Revision Gap Down
JBIO Jade Biosciences	2.267 of 5 stars	$25.06 +2.2%	$31.17 +24.4%	N/A	$1.24B	N/A	N/A	20	Analyst Revision
MLTX MoonLake Immunotherapeutics	3.4286 of 5 stars	$17.07 -2.8%	$23.08 +35.2%	-50.3%	$1.22B	N/A	N/A	2	Earnings Report Analyst Forecast Analyst Revision
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLN) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silence Therapeutics (SLN) Competitors

SLN vs. OLMA, JBIO, MLTX, CALT, and MPLT

How does Silence Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Silence Therapeutics compare to Jade Biosciences?

Summary

How does Silence Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Silence Therapeutics compare to Calliditas Therapeutics AB (publ)?

Summary

How does Silence Therapeutics compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silence Therapeutics (SLN) Competitors

SLN vs. OLMA, JBIO, MLTX, CALT, and MPLT

How does Silence Therapeutics compare to Olema Pharmaceuticals?

Do analysts rate SLN or OLMA?

Does the media prefer SLN or OLMA?

Which has higher earnings and valuation, SLN or OLMA?

Is SLN or OLMA more profitable?

Which has more risk & volatility, SLN or OLMA?

Do insiders & institutionals hold more shares of SLN or OLMA?

Summary

How does Silence Therapeutics compare to Jade Biosciences?

Do insiders & institutionals hold more shares of SLN or JBIO?

Which has more risk & volatility, SLN or JBIO?

Does the media prefer SLN or JBIO?

Do analysts rate SLN or JBIO?

Which has higher earnings and valuation, SLN or JBIO?

Is SLN or JBIO more profitable?

Summary

How does Silence Therapeutics compare to MoonLake Immunotherapeutics?

Do institutionals & insiders hold more shares of SLN or MLTX?

Which has more volatility and risk, SLN or MLTX?

Does the media prefer SLN or MLTX?

Do analysts recommend SLN or MLTX?

Which has stronger earnings & valuation, SLN or MLTX?

Is SLN or MLTX more profitable?

Summary

How does Silence Therapeutics compare to Calliditas Therapeutics AB (publ)?

Which has stronger earnings & valuation, SLN or CALT?

Do institutionals & insiders hold more shares of SLN or CALT?

Does the media prefer SLN or CALT?

Do analysts recommend SLN or CALT?

Is SLN or CALT more profitable?

Which has more volatility and risk, SLN or CALT?

Summary

How does Silence Therapeutics compare to Maplight Therapeutics?

Which has preferable valuation & earnings, MPLT or SLN?

Do insiders and institutionals believe in MPLT or SLN?

Does the media favor MPLT or SLN?

Do analysts rate MPLT or SLN?

Is MPLT or SLN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools